Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"An Open-label, Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors."

NCT00493155 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00493155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00493155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"An Open-label, Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors."
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2005
Completion date
February 28, 2009
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms